George Lundberg, MD Contributing Editor at Cancer Commons

  •   George Lundberg, MD

    Healio outlines results from a Stanford University study suggesting that a type of treatment known as CAR T-cell therapy is promising for children with diffuse midline gliomas. The treatment is still in an early phase of testing in humans.

    .

  •   George Lundberg, MD

    This scientific editorial article from the Journal of Clinical Oncology discusses results from a clinical trial suggesting that addition of a treatment called transarterial radioembolization to standard treatment was not effective for people with colorectal cancer liver metastases that cannot be removed by surgery.

    .

  •   George Lundberg, MD

    This scientific manuscript from Cureus reports results from a Toronto cancer center suggesting that stereotactic radiotherapy offers another option for palliative treatment of inoperable pancreatic cancer.

    .

  •   George Lundberg, MD

    This resource from the U.S. Food and Drug Administration (FDA) lists recent drug approval announcements for liver cancer and related conditions. It also provides link to information about additional approvals that may not be announced.

    .

  •   George Lundberg, MD

    This scientific report from medRxiv demonstrates how self-reported data from brain cancer patients could be used to run “virtual trials” that complement traditional clinical trials by generating knowledge that could help inform precision cancer treatment.

    .

  •   George Lundberg, MD

    This scientific report from Neuro-Oncology outlines findings from a large, randomized clinical trial showing that the drug veliparib (a kind of drug known as a PARP inhibitor) added to radiotherapy and temozolomide did not improve progression-free survival in unmethylated glioblastoma.

    .

  •   George Lundberg, MD

    TheSocialMedwork outlines several new drugs for treating chronic lymphocytic leukemia, including Brukinsa (zanubrutinib).

    .

  •   George Lundberg, MD

    This academic review paper from Blood Cancer Journal outlines many recent advances in the treatment of Hodgkin lymphoma, including for the 15-30% of patients who do not respond or relapse after conventional treatment.

    .

  •   George Lundberg, MD

    Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

    .

  •   George Lundberg, MD

    Oncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.

    .

    .